tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Jordan ML et al. FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. 1993 Transplant. Proc. pmid:7679827
Klintmalm GB et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679828
Lane BC et al. Evaluation of calcineurin's role in the immunosuppressive activity of FK 506, related macrolactams, and cyclosporine. 1993 Transplant. Proc. pmid:7679829
Celli S et al. Long-term survival of heart and liver xenografts with splenectomy and FK 506. 1993 Transplant. Proc. pmid:7679830
Japanese study of FK 506 on kidney transplantation: results of late phase II study. 1993 Transplant. Proc. pmid:7679831
Tamura K et al. Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production. 1993 Clin. Exp. Immunol. pmid:7680293
Armitage JM et al. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. 1993 J. Thorac. Cardiovasc. Surg. pmid:7680396
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Xu RX et al. Heteronuclear 3D NMR studies of water bound to an FK506 binding protein/immunosuppressant complex. 1993 Biochemistry pmid:7680570
López-Gil JA and García Sáiz M [FK506: an immunosuppressor for the '90's?]. 1993 Med Clin (Barc) pmid:7505871
Kagayama A et al. Oral absorption of FK506 in rats. 1993 Pharm. Res. pmid:7505939
Kim YI et al. Augmentation of hepatocyte proliferation by immunosuppressant pretherapy is associated with up-regulation of malondialdehyde production. 1993 Res Exp Med (Berl) pmid:7506444
Hytiroglou P et al. FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. 1993 Transplantation pmid:7506452
Hutchison KA et al. FK506 binding to the 56-kilodalton immunophilin (Hsp56) in the glucocorticoid receptor heterocomplex has no effect on receptor folding or function. 1993 Biochemistry pmid:7682438
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Shorrock C and Neuberger J The changing face of liver transplantation. 1993 Gut pmid:7682532
Nakajima J [The immunosuppressive effects of FK506 on single lung allotransplantation in Japanese monkey (Macaca fuscata)]. 1993 Nihon Kyobu Geka Gakkai Zasshi pmid:7690829
Wenzel-Seifert K and Seifert R Partial inhibition of human neutrophil activation by FK-506 at supratherapeutic concentrations. 1993 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7690907
Liu J FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. 1993 Immunol. Today pmid:7691065
Takada K et al. Distribution characteristics of immunosuppressants FK506 and cyclosporin A in the blood compartment. 1993 Biopharm Drug Dispos pmid:7508273
Thomson AW et al. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat. 1993 Immunopharmacol Immunotoxicol pmid:7693791
Tzakis AG et al. Intestinal transplantation in children under FK 506 immunosuppression. 1993 J. Pediatr. Surg. pmid:7693907
Kawauchi M et al. Prolonged survival of orthotopically transplanted heart xenograft in infant baboons. 1993 J. Thorac. Cardiovasc. Surg. pmid:7693999
Shutter LA et al. Cortical blindness and white matter lesions in a patient receiving FK506 after liver transplantation. 1993 Neurology pmid:7694189
Dawson TM et al. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7694293
Lemster B et al. Blood lymphocytes of autoimmune disease patients receiving FK506 exhibit normal ex vivo cytokine gene expression and proliferative responses. 1993 Immunol. Lett. pmid:7510265
Parent SA et al. Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae. 1993 J. Gen. Microbiol. pmid:7510323
Asami M et al. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. 1993 Biochem. Biophys. Res. Commun. pmid:7685169
Metcalfe S et al. Prodigiosin 25C: effect in in vitro models for T cell activation and T cell cycling and in vivo for rat heart allografts. 1993 Int. Arch. Allergy Immunol. pmid:7685216
Bumgardner GL and Roberts JP New immunosuppressive agents. 1993 Gastroenterol. Clin. North Am. pmid:7685324
Ahmed SS et al. Adrenochrome reaction implicates oxygen radicals in metabolism of cyclosporine A and FK-506 in rat and human liver microsomes. 1993 J. Pharmacol. Exp. Ther. pmid:7685382
Sewell KL Immunotherapy and other novel therapies, including biologic response modifiers, apheresis, and dietary modifications. 1993 Curr Opin Rheumatol pmid:7685614
Wagner JA et al. Failure of FK 506 to suppress the T cell-mediated immunity of mice to Listeria monocytogenes. 1993 Clin. Exp. Immunol. pmid:7685672
Henke W and Jung K Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. 1993 Biochem. Pharmacol. pmid:7690566
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Altmeyer A and Dumont FJ Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma. 1993 Cytokine pmid:7687472
Przepiorka D et al. Bronchiolitis obliterans organizing pneumonia in a BMT patient receiving FK506. 1993 Bone Marrow Transplant. pmid:7687503
Bram RJ et al. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. 1993 Mol. Cell. Biol. pmid:7687744
Heitman J et al. The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. 1993 Mol. Cell. Biol. pmid:7687745
Hirakawa K et al. [The effect of perioperative portal venous inoculation with donor lymphocytes in combination with immunosuppressive agents on rat cardiac allograft survivals]. 1993 Nihon Geka Gakkai Zasshi pmid:7688065
Fesik SW NMR structure-based drug design. 1993 J. Biomol. NMR pmid:7689377
McManus BM et al. Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. 1993 Clin. Immunol. Immunopathol. pmid:7689428
Namiki Y et al. Tautomeric phenomenon of a novel potent immunosuppressant (FK506) in solution. I. Isolation and structure determination of tautomeric compounds. 1993 J. Antibiot. pmid:7689551
Kondo T et al. [Antitumor sensitivity test, subrenal capsule assay using FK-506: preliminary report]. 1993 Nihon Geka Gakkai Zasshi pmid:7689693
Ibarra F et al. Bidirectional regulation of Na+,K(+)-ATPase activity by dopamine and an alpha-adrenergic agonist. 1993 Proc. Natl. Acad. Sci. U.S.A. pmid:7678337
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Herold KC et al. Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. 1993 Transplantation pmid:7678356
Holman MJ et al. FK506-associated thrombotic thrombocytopenic purpura. 1993 Transplantation pmid:7678357
Kawai M et al. Structure-activity profiles of macrolactam immunosuppressant FK-506 analogues. 1993 FEBS Lett. pmid:7678400